Q-Line Biotech IPO fully subscribed within an hour of opening; check allotment and listing date

Q-Line Biotech IPO: The initial public offering of healthcare solutions provider Q-Line Biotech was fully subscribed within an hour of opening for subscription on Thursday, May 21.

The issue has received bids for 72,19,600 shares as against 44,72,000 shares on offer, leading to 1.61 times subscription, according to the NSE data until 11:19 am.

The ₹214.48 crore initial share sale is only a fresh issue of 62.53 lakh shares with a face value of ₹10 each.

The company intends to utilise net proceeds to fund the working capital requirements, debt repayment, and general corporate purposes.

Q-Line Biotech IPO: Price band and lot size

The price band has been fixed at ₹326 to ₹343 per share. A lot consists of 400 shares, and the least investment for an individual investor is two lots, or 800 shares.

Q-Line Biotech IPO: Allotment and listing date

Prior to the IPO, the company raised ₹61.09 crore from anchor investors. It allotted over 17.81 lakh shares to Abakkus Mutual Fund, Bharat Venture Opportunities Fund, Carnelian Capital, 360 ONE, and HDFC Bank at the upper price band of ₹343 per share.

It is engaged in the business of developing, manufacturing and marketing an array of reagents (including kits and POC devices) and consumables and manufacturing and supplying diagnostic equipment for different diagnostic healthcare needs.

On the financial front, the firm had posted a revenue from operations of ₹313.78 crore and profit after tax of ₹28.13 crore in the financial year 2024-25.

The company's shares will list on the SME platform of NSE, Emerge.

Hem Securities Ltd is the sole book-running lead manager for the public issue.

Q-Line Biotec IPO GMP